[go: up one dir, main page]

MX2010001723A - Formulations of antibodies and fc-fusion molecules using polycations. - Google Patents

Formulations of antibodies and fc-fusion molecules using polycations.

Info

Publication number
MX2010001723A
MX2010001723A MX2010001723A MX2010001723A MX2010001723A MX 2010001723 A MX2010001723 A MX 2010001723A MX 2010001723 A MX2010001723 A MX 2010001723A MX 2010001723 A MX2010001723 A MX 2010001723A MX 2010001723 A MX2010001723 A MX 2010001723A
Authority
MX
Mexico
Prior art keywords
polycations
formulations
antibodies
fusion molecules
antibody
Prior art date
Application number
MX2010001723A
Other languages
Spanish (es)
Inventor
Tiansheng Li
Pavel Bondarenko
Christopher James Sloey
Gang Xiao
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2010001723A publication Critical patent/MX2010001723A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates, in general, to methods for preparing antibody and Fc-fusion molecule formulations, wherein the antibody or Fc-fusion molecule is in a formulation comprising polycations. The invention also provides compositions comprising an antibody or Fc-fusion molecule and a polycation.
MX2010001723A 2007-08-17 2008-08-15 Formulations of antibodies and fc-fusion molecules using polycations. MX2010001723A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95651407P 2007-08-17 2007-08-17
PCT/US2008/073250 WO2009026122A1 (en) 2007-08-17 2008-08-15 Formulations of antibodies and fc-fusion molecules using polycations

Publications (1)

Publication Number Publication Date
MX2010001723A true MX2010001723A (en) 2010-04-30

Family

ID=40014979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001723A MX2010001723A (en) 2007-08-17 2008-08-15 Formulations of antibodies and fc-fusion molecules using polycations.

Country Status (6)

Country Link
EP (1) EP2190476A1 (en)
JP (1) JP2010536786A (en)
AU (1) AU2008289225A1 (en)
CA (1) CA2696049A1 (en)
MX (1) MX2010001723A (en)
WO (1) WO2009026122A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
PL3295957T3 (en) 2010-01-15 2020-03-31 Kirin-Amgen, Inc. Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
CN102585016B (en) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 Immune fusion protein capable of inhibiting T and B lymphocyte functions and preparation method and application thereof
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
UA115789C2 (en) * 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Antibody formulations and uses thereof
CN103232542B (en) * 2013-02-01 2015-05-13 殷勇 Double-target chimeric protein
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
EP3064213A4 (en) * 2013-10-28 2017-04-26 Terumo Kabushiki Kaisha Protein aqueous suspension
CN106999510B (en) 2014-10-01 2021-04-30 伊格尔生物制品有限公司 Polysaccharide and nucleic acid formulations containing viscosity reducing agents
BR112019018022A2 (en) * 2017-03-01 2020-06-02 Medimmune Limited MONOCLONAL ANTIBODY FORMULATIONS
JP7104929B2 (en) * 2017-07-24 2022-07-22 テルモ株式会社 Method for producing complex containing medical protein and polyamino acid, and complex containing medical protein and polyamino acid
WO2024181580A1 (en) * 2023-03-02 2024-09-06 国立研究開発法人科学技術振興機構 Lipid nanoparticles, pharmaceutical composition, and production method for lipid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
DE4110409C2 (en) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int New protein-polycation conjugates
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents

Also Published As

Publication number Publication date
CA2696049A1 (en) 2009-02-26
WO2009026122A1 (en) 2009-02-26
EP2190476A1 (en) 2010-06-02
JP2010536786A (en) 2010-12-02
AU2008289225A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MX2010001723A (en) Formulations of antibodies and fc-fusion molecules using polycations.
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
PH12015501848A1 (en) Binding agents
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MY174493A (en) Binding agents
MX2009006594A (en) Formulations.
EA201170659A1 (en) ANTIBODIES TO TGF-VETA RECEPTOR II
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MY161909A (en) Anti-her3 antibodies and uses thereof
TN2010000213A1 (en) Wise binding antibodies and epitopes
MX336682B (en) Antibodies against human csf-1r and uses thereof.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2018008680A (en) Tdp-43 specific binding molecules.
EA201390145A1 (en) CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
WO2012025873A3 (en) STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
UA99339C2 (en) Antibody that specifically binds to human tyrp1
TW200642700A (en) Chemically defined stabiliser
TW200621721A (en) Methods of preparing indazole compounds
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
WO2010136483A3 (en) Antigen-binding proteins
MX366622B (en) Stable pharmaceutical composition of tnfr:fc fusion protein.
WO2009035959A3 (en) Radiofluorination methods
WO2009132251A3 (en) Methods and compositions comprising anti-idiotypic antibodies to anti-mmp-14 antibodies

Legal Events

Date Code Title Description
FA Abandonment or withdrawal